You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2024

Claims for Patent: 9,056,915

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,056,915

Title:	Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
Abstract:	Antigen binding proteins that interact with Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) are described. Methods of treating hypercholesterolemia and other disorders by administering a pharmaceutically effective amount of an antigen binding protein to PCSK9 are described. Methods of detecting the amount of PCSK9 in a sample using an antigen binding protein to PCSK9 are described.
Inventor(s):	Jackson; Simon Mark (San Carlos, CA), Walker; Nigel Pelham Clinton (Burlingame, CA), Piper; Derek Evan (Santa Clara, CA), Shan; Bei (Redwood City, CA), Shen; Wenyan (Palo Alto, CA), King; Chadwick Terence (North Vancouver, CA), Ketchem; Randal Robert (Snohomish, WA), Mehlin; Christopher (Seattle, WA), Carabeo; Teresa Arazas (New York, NY)
Assignee:	Amgen Inc. (Thousand Oaks, CA)
Application Number:	14/459,768
Patent Claims:	1. A monoclonal antibody that binds to an epitope on PCSK9, wherein the epitope comprises at least one of the following residues: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO:3, and wherein said monoclonal antibody comprises: a heavy chain variable region; and a light chain variable region; wherein the monoclonal antibody blocks binding interaction between PCSK9 and EGFa domain of LDLR. 2. The monoclonal antibody of claim 1, wherein the light chain variable region comprises at least one selected from the group consisting of L48, S51, Y93, and S98 of SEQ ID NO:12. 3. The monoclonal antibody of claim 1, wherein said monoclonal antibody is a human or a humanized monoclonal antibody. 4. The monoclonal antibody of claim 1, wherein said monoclonal antibody binds to a D374Y variant of a PCSK9 protein comprising SEQ ID NO: 1. 5. The monoclonal antibody of claim 1, wherein said monoclonal antibody is an IgG. 6. The monoclonal antibody of claim 1, wherein said light chain variable region is connected to a human kappa amino acid sequence. 7. The monoclonal antibody of claim 1, wherein the monoclonal antibody comprises an intact immunoglobulin. 8. The monoclonal antibody of claim 1, wherein the monoclonal antibody comprises a fragment of an intact immunoglobulin. 9. The monoclonal antibody of claim 1, wherein the monoclonal antibody comprises the amino acid sequence of SEQ ID NO: 157. 10. A pharmaceutical composition comprising: a pharmaceutically acceptable carrier; and a monoclonal antibody that binds to an epitope on PCSK9, wherein the epitope comprises at least one of the following residues: S153, I154, P155, R194, D238, A239, I369, S372, D374, C375, T377, C378, F379, V380, or S381 of SEQ ID NO:3, and wherein said monoclonal antibody comprises a heavy chain variable region and a light chain variable region; wherein the monoclonal antibody blocks binding interaction between PCSK9 and EGFa domain of LDLR. 11. The monoclonal antibody of claim 1, wherein the heavy chain variable region comprises at least one amino acid in the specified position selected from the group consisting of T28, S30, S31, Y32, S54, S55, S56, Y57, I58, S59, Y60, N74, A75, R98, Y100, F102, W103, S104, A105, Y106, Y107, D108, A109, and D111 of SEQ ID NO: 67. 12. The monoclonal antibody of claim 11, wherein the light chain variable region comprises at least one selected from the group consisting of L48, S51, Y93, and S98 of SEQ ID NO: 12. 13. The monoclonal antibody of claim 12, wherein said monoclonal antibody is a human or a humanized monoclonal antibody. 14. The monoclonal antibody of claim 12, wherein said monoclonal antibody binds to a D374Y variant of a PCSK9 protein comprising SEQ ID NO: 1. 15. The monoclonal antibody of claim 12, wherein said monoclonal antibody is an IgG. 16. The monoclonal antibody of claim 12, wherein said light chain variable region is connected to a human kappa amino acid sequence. 17. The monoclonal antibody of claim 12, wherein the monoclonal antibody comprises an intact immunoglobulin. 18. The monoclonal antibody of claim 12, wherein the monoclonal antibody comprises a fragment of an intact immunoglobulin. 19. The monoclonal antibody of claim 12, wherein the monoclonal antibody comprises the amino acid sequence of SEQ ID NO: 157. 20. The monoclonal antibody of claim 12, further comprising a HCDR1 that is a HCDR1 in SEQ ID NO:60 according to the definition of Chothia. 21. The pharmaceutical composition of claim 10, wherein the heavy chain variable region comprises at least one amino acid in the specified position selected from the group consisting of T28, S30, S31, Y32, S54, S55, S56, Y57, I58, S59, Y60, N74, A75, R98, Y100, F102, W103, S104, A105, Y106, Y107, D108, A109, and D111 of SEQ ID NO: 67. 22. The pharmaceutical composition of claim 10, wherein the light chain variable region comprises at least one amino acid in the specified position selected from the group consisting of L48, S51, Y93, and S98 of SEQ ID NO: 12. 23. The pharmaceutical composition of claim 21, wherein the light chain variable region comprises at least one amino acid in the specified position selected from the group consisting of L48, S51, Y93, and S98 of SEQ ID NO: 12.

Details for Patent 9,056,915

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Amgen Inc.	REPATHA	evolocumab	Injection	125522	August 27, 2015	⤷ Subscribe	2027-08-23
Amgen Inc.	REPATHA	evolocumab	Injection	125522	July 08, 2016	⤷ Subscribe	2027-08-23
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 9,056,915

Subscribe to access the full database, or Subscribe
Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2009026558	⤷ Subscribe
United States of America	9920134	⤷ Subscribe
United States of America	9493576	⤷ Subscribe
United States of America	9045547	⤷ Subscribe
United States of America	8981064	⤷ Subscribe
United States of America	8889834	⤷ Subscribe
United States of America	8883983	⤷ Subscribe
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.